

Matti Aapro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8890351/publications.pdf>

Version: 2024-02-01

94
papers

5,397
citations

126907

33
h-index

82547

72
g-index

96
all docs

96
docs citations

96
times ranked

6038
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient blood management in oncology in the Russian Federation: Resolution to improve oncology care. <i>Journal of Cancer Policy</i> , 2022, 31, 100315.	1.4	0
2	Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO). <i>European Journal of Cancer</i> , 2022, 166, 126-133.	2.8	8
3	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. <i>Current Cancer Drug Targets</i> , 2022, 22, 806-824.	1.6	2
4	Changing the landscape of European School of Oncologyâ€™European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. <i>Future Oncology</i> , 2022, 18, 2857-2864.	2.4	1
5	Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103143.	4.4	5
6	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. <i>Oncologist</i> , 2021, 26, e1073-e1082.	3.7	20
7	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	1.4	22
8	Educational contribution of the College of the European School of Oncology to the Latin American Oncologists. <i>Future Oncology</i> , 2021, 17, 2981-2987.	2.4	1
9	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102798.	4.4	9
10	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. <i>Oncologist</i> , 2020, 25, e589-e597.	3.7	21
11	The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102976.	4.4	5
12	Essential Role of Patient Blood Management in a Pandemic: A Call for Action. <i>Anesthesia and Analgesia</i> , 2020, 131, 74-85.	2.2	131
13	The clinical training centers fellowships: a European School of Oncology career development program (2013â€™2019). <i>Future Oncology</i> , 2020, 16, 1969-1976.	2.4	5
14	Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure. <i>BioDrugs</i> , 2020, 34, 255-263.	4.6	19
15	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2020, 36, 1124-1128.	1.3	5
16	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. <i>Lancet Oncology</i> , The, 2019, 20, 1482-1485.	10.7	2
17	Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. <i>BioDrugs</i> , 2019, 33, 635-645.	4.6	9
18	Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. <i>Future Oncology</i> , 2019, 15, 1067-1084.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study. <i>European Journal of Cancer Care</i> , 2019, 28, e13034.	1.5	3
20	Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. <i>Leukemia Research</i> , 2019, 81, 35-42.	0.8	10
21	Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). <i>Breast</i> , 2019, 45, 7-14.	2.2	11
22	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day (24h), per-guidelines (24-72h), and late (>72h): findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2019, 27, 2301-2312.		
23	Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts. <i>Supportive Care in Cancer</i> , 2018, 26, 35-37.	2.2	4
24	Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information. <i>Supportive Care in Cancer</i> , 2018, 26, 1-2.	2.2	0
25	CINV: still troubling patients after all these years. <i>Supportive Care in Cancer</i> , 2018, 26, 5-9.	2.2	124
26	Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction. <i>Supportive Care in Cancer</i> , 2018, 26, 3-4.	2.2	2
27	<sc>MONITOR</sc> GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis. <i>European Journal of Haematology</i> , 2018, 100, 241-246.	2.2	6
28	Continuity and diversity. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 121, A2.	4.4	0
29	Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. <i>Cancer Reports</i> , 2018, 1, e1127.	1.4	31
30	Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. <i>BMC Cancer</i> , 2018, 18, 917.	2.6	15
31	Anaemia in Cancer Patients. , 2018, , 319-322.		0
32	The Impact of Biosimilars in Supportive Care in Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 20.	0.0	6
33	A Practical Approach to Fatigue Management in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 275-285.	2.3	34
34	Geriatric factors and outcomes in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 74, 96-97.	2.8	1
35	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2~) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	2.2	4
36	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. <i>Supportive Care in Cancer</i> , 2017, 25, 1127-1135.	2.2	37

#	ARTICLE	IF	CITATIONS
37	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017, 25, 3295-3304.	2.2	64
38	Towards sustainable cancer care: Reducing inefficiencies, improving outcomes – A policy report from the All.Can initiative. <i>Journal of Cancer Policy</i> , 2017, 13, 47-64.	1.4	36
39	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	2.8	25
40	Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). <i>Journal of Geriatric Oncology</i> , 2017, 8, 86-95.	1.0	22
41	The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer. <i>Biomedicine Hub</i> , 2017, 2, 1-3.	1.2	0
42	Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. <i>New England Journal of Medicine</i> , 2016, 374, 1356-1367.	27.0	314
43	Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. <i>Oncologist</i> , 2016, 21, 494-502.	3.7	15
44	Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 987-993.	1.2	55
45	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016, 24, 911-925.	2.2	62
46	Treatment of the Elderly Head and Neck Cancer Patient. , 2016, , 743-751.		0
47	Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety. <i>Oncologist</i> , 2015, 20, 450-458.	3.7	103
48	Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 839-848.e4.	1.2	121
49	Modeling of treatment response to erythropoiesis-stimulating agents in older (age ≥ 70 years) and younger (age < 70 years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study. <i>Journal of Geriatric Oncology</i> , 2013, 4, 196-201.	1.0	0
50	Biosimilars in oncology: current and future perspectives. <i>GaBI Journal</i> , 2013, 2, 91-93.	0.3	15
51	Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. <i>Therapeutic Advances in Urology</i> , 2012, 4, 85-101.	2.0	14
52	Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 95-105.	3.2	53
53	Importance of monitoring renal function in patients with cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 235-240.	7.7	55
54	Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results. <i>Cancer Treatment Reviews</i> , 2012, 38, 120-126.	7.7	35

#	ARTICLE	IF	CITATIONS
55	Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. <i>Cancer Treatment Reviews</i> , 2012, 38, 815-824.	7.7	15
56	SIOG (International Society of Geriatric Oncology) and anthracycline use in the elderly. <i>European Journal of Cancer</i> , Supplement, 2011, 9, 30-35.	2.2	0
57	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	10.7	571
58	Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis. <i>Breast</i> , 2011, 20, 468-474.	2.2	47
59	Antiemetic research: future directions. <i>Supportive Care in Cancer</i> , 2011, 19, 49-55.	2.2	46
60	Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 184-197.	4.4	23
61	Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 198-200.	4.4	15
62	Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. <i>Supportive Care in Cancer</i> , 2010, 18, 529-541.	2.2	82
63	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 203-210.	4.4	27
64	Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases. <i>Oncologist</i> , 2010, 15, 1147-1158.	3.7	42
65	Update on Erythropoiesis-Stimulating Agents and Clinical Trials in Oncology. <i>Oncologist</i> , 2009, 14, 6-15.	3.7	25
66	An Update on Twenty Years of Anemia Management with Erythropoiesis-Stimulating Agents in Nephrology and Oncology/Hematology. <i>Oncologist</i> , 2009, 14, 1-5.	3.7	98
67	Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. <i>European Journal of Cancer</i> , 2009, 45, 1603-1615.	2.8	54
68	What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?. <i>European Journal of Cancer</i> , 2009, 45, 2984-2991.	2.8	16
69	Editorial. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 1-3.	2.5	3
70	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. <i>Supportive Care in Cancer</i> , 2008, 16, 193-200.	2.2	15
71	Overcoming challenges associated with chemotherapy treatment in the senior adult population. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, S1-S8.	4.4	30
72	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , 2008, 44, 353-365.	2.8	17

#	ARTICLE	IF	CITATIONS
73	Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer Anemia and the Value of Erythropoietin (BRAVE) Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 592-598.	1.6	107
74	Breast Cancer in the Elderly. <i>Journal of Clinical Oncology</i> , 2007, 25, 1882-1890.	1.6	151
75	Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. <i>European Journal of Cancer</i> , 2007, 43, 510-519.	2.8	70
76	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , 2007, 43, 14-34.	2.8	224
77	International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. <i>European Journal of Cancer</i> , 2007, 43, 852-858.	2.8	83
78	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2007, 8, 1101-1115.	10.7	313
79	International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients An Analysis of the Medical Literature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1832-1843.	1.6	210
80	Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care. <i>Supportive Care in Cancer</i> , 2007, 15, 1325-1329.	2.2	5
81	Erythropoietin: effects on life expectancy in patients with cancer-related anaemia. <i>Current Medical Research and Opinion</i> , 2006, 22, S5-S13.	1.9	3
82	Effect of Treatment with Epoetin Beta on Thromboembolic Events in Anemic Patients with Cancer: A Metaanalysis. <i>Supportive Cancer Therapy</i> , 2006, 4, 49-55.	0.3	10
83	What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?. <i>Oncologist</i> , 2006, 11, 1-3.	3.7	129
84	Use of comprehensive geriatric assessment in older cancer patients:. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 241-252.	4.4	1,002
85	5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis. <i>Cancer</i> , 2005, 104, 1-18.	4.1	31
86	Chemotherapy-Induced Emesis in Elderly Cancer Patients: The Role of 5-HT ₃ -Receptor Antagonists in the First 24 Hours. <i>Gerontology</i> , 2005, 51, 287-296.	2.8	22
87	5-HT ₃ -Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment. <i>Oncology</i> , 2005, 69, 97-109.	1.9	76
88	Optimising antiemetic therapy: what are the problems and how can they be overcome?. <i>Current Medical Research and Opinion</i> , 2005, 21, 885-897.	1.9	34
89	Evolving Treatment Strategies for Anaemia in Cancer: Experience with Epoetin Beta. <i>Oncology</i> , 2004, 67, 17-22.	1.9	3
90	Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting. <i>Oncologist</i> , 2004, 9, 673-686.	3.7	73

#	ARTICLE	IF	CITATIONS
91	Treatment for Anthracyclineâ€retreated Metastatic Breast Cancer. <i>Oncologist</i> , 2002, 7, 4-12.	3.7	55
92	Pharmacology. <i>European Journal of Cancer</i> , 2001, 37, 251-252.	2.8	61
93	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 223-230.	1.2	19
94	Methodological issues in antiemetic studies. <i>Investigational New Drugs</i> , 1993, 11, 243-253.	2.6	26